MedTrace Logo

ALPP CAR-T Cells for ALPP-Positive Advanced Solid Tumors

NCT06556108 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2026-01-20

No results posted yet for this study

Summary

Alkaline phosphatase (ALP) is a membrane-bound glycoprotein that catalyzes the hydrolysis of phosphates at alkaline pH values. As one of the earliest discovered oncofetal antigens, ALP has emerged as a significant biomarker for various malignant tumors, such as ovarian cancer, breast cancer, trophoblastic tumors, germ cell tumors, endometrial cancer, testicular tumors, cervical intraepithelial neoplasia, and gastrointestinal tumors.

Conditions

Interventions

BIOLOGICAL

ALPP CAR-T cells

T cells genetically engineered with a CAR targeting ALPP (ALPP CAR) that display specific reactivity against ALPP target cells

DRUG

Fludarabine

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

DRUG

Cyclophosphamide

Part of the non-myeloablative lymphocyte-depleting preparative regimen.

Sponsors & Collaborators

  • Xinqiao Hospital of Chongqing

    lead OTHER

Principal Investigators

  • Qingzhu Jia, M.D. · Xinqiao Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-01
Primary Completion
2025-01-30
Completion
2025-07-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06556108 on ClinicalTrials.gov